Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

PepsiCo shares could remain on watchlists after surging last week following a better-than-expected earnings report and outlook from the beverage and snack food giant. Monitor these key post-earnings ...